Patients eligible for hormone ablation therapy who are prescribed Firmagon will be followed for a maximum of 3 years to estimate the progression free survival. Data on testosteron levels, QoL and LUTS will be collected if this information is available. Safety information (adverse events) will be collected.
Study Type
OBSERVATIONAL
Enrollment
274
To estimate the progression-free survival (PFS) failure rate
Time frame: Maximum 3 years
To enhance the knowledge on known undesirable effects under routine conditions and to obtain further knowledge about so far unknown and rare undesired effects
Time frame: Every 3 months (during 3 years)
To prescribe the change in patient's quality of life (QoL) during therapy.
Time frame: From study start and after 6 months
To assess the improvement of IPSS from baseline after 3 months of Firmagon therapy and at end-of-therapy
Time frame: From study start, after 3 months and at end of treatment
To assess the reduction of prostate volume (neoadjuvant therapy)
Time frame: Fom baseline after 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Jeroen Bosch Ziekenhuis, locatie Carolus
's-Hertogenbosch, Netherlands
Flevoziekenhuis
Almere Stad, Netherlands
Bovenij Ziekenhuis
Amsterdam, Netherlands
Wilhelminaziekenhuis
Assen, Netherlands
Rode Kruis Ziekenhuis
Beverwijk, Netherlands
Tergooiziekenhuizen
Blaricum, Netherlands
Amphia Ziekenhuis
Breda, Netherlands
Ljsselland Ziekenhuis
Capelle aan den IJssel, Netherlands
Reinier de Graaf Groep
Delft, Netherlands
Deventer Ziekenhuis
Deventer, Netherlands
...and 37 more locations